CSIMarket
 


Xencor Inc  (XNCR)
Other Ticker:  
 
 

XNCR's Revenue Growth by Quarter and Year

Xencor Inc's Revenue results by quarter and year




XNCR Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 44.69 21.61 154.02 41.85
III Quarter September 59.16 27.30 19.68 35.37
II Quarter June 45.52 30.18 67.45 13.09
I Quarter March 18.96 85.50 33.97 32.39
FY   168.33 164.59 275.12 122.70



XNCR Revenue fourth quarter 2023 Y/Y Growth Comment
Xencor Inc reported Revenue surge of 106.8% year on year in the fourth quarter 2023, to $ 44.69 millions, this is lower than Xencor Inc's recent average Revenue surge of 111.69%.

Looking into fourth quarter 2023 results within Major Pharmaceutical Preparations industry 72 other companies have achieved higher Revenue growth. While Xencor Inc' s Revenue doubling of 106.8% ranks overall at the positon no. 1823 in the fourth quarter 2023.




XNCR Revenue ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December 106.8 % -85.97 % 268.03 % 1088.92 %
III Quarter September 116.7 % 38.72 % -44.36 % 62.55 %
II Quarter June 50.83 % -55.26 % 415.28 % -32.84 %
I Quarter March -77.82 % 151.69 % 4.88 % -71.06 %
FY   2.27 % -40.18 % 124.22 % -21.7 %

Financial Statements
Xencor Inc's fourth quarter 2023 Revenue $ 44.69 millions XNCR's Income Statement
Xencor Inc's fourth quarter 2022 Revenue $ 21.61 millions Quarterly XNCR's Income Statement
New: More XNCR's historic Revenue Growth >>


XNCR Revenue (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December -24.46 % -20.84 % 682.62 % 18.32 %
III Quarter September 29.96 % -9.54 % -70.82 % 170.21 %
II Quarter June 140.08 % -64.7 % 98.56 % -59.59 %
I Quarter March -12.26 % -44.49 % -18.83 % 820.17 %
FY (Year on Year)   2.27 % -40.18 % 124.22 % -21.7 %




Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #73
Healthcare Sector #213
Overall #1823

Revenue Y/Y Growth Statistics
High Average Low
992.56 % 111.69 % -69.98 %
(June 30. 2016)   (Mar 31 2023)
Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #73
Healthcare Sector #213
Overall #1823
Revenue Y/Y Growth Statistics
High Average Low
992.56 % 111.69 % -69.98 %
(June 30. 2016)   (Mar 31 2023)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Xencor Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
868 % 112.91 % -100 %
(Mar 31 2019)  


XNCR's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2023 Xencor Inc disclosed fall in Revenue sequentially by -24.46% to $ 44.69 millions, from $ 59.16 millions achived a quarter before.

But that's not big concern, as IV. Quarter Revenue always seem to slow in this quarter Thomas  L. Williams, a business veteran allocated in Edinburgh told.

Within Major Pharmaceutical Preparations industry 67 other companies have achieved higher Revenue quarter on quarter growth. While Xencor Inc's Revenue growth quarter on quarter, overall rank is 1769.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #68
Healthcare Sector #211
Overall #1769
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #68
Healthcare Sector #211
Overall #1769
Revenue Q/Q Growth Statistics
High Average Low
868 % 112.91 % -100 %
(Mar 31 2019)  


XNCR's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2023 Xencor Inc reported fall in Revenue from the previous quarter by -24.46% to $ 44.69 millions, from $ 59.16 millions achived in the previous reporting period.

It's not big issue, as Xencor Inc's Revenue generally tend to dip in this quarter.

Within Major Pharmaceutical Preparations industry 67 other companies have achieved higher Revenue quarter on quarter growth. While Xencor Inc's Revenue growth quarter on quarter, overall rank is 1769.


Xencor Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Revenue 12 Months Ending $ 168.34 $ 145.26 $ 113.39 $ 98.05 $ 164.58
Y / Y Revenue Growth (TTM) 2.28 % -51.09 % -60.81 % -69.98 % -40.18 %
Year on Year Revenue Growth Overall Ranking # 1813 # 233 # 387 # 200 # 158
Seqeuential Revenue Change (TTM) 15.89 % 28.1 % 15.65 % -40.43 % -44.58 %
Seq. Revenue Growth (TTM) Overall Ranking # 1823 # 1713 # 2871 # 1116 # 342




Cumulative Revenue growth Comment
Although Xencor Inc's Annual Revenue growth year on year were below company's average 111.69% , Revenue announced in the Dec 31 2023 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 2.28% year on year, from -51.09% in Sep 30 2023.

In the Healthcare sector 211 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 233 to 1813.

Revenue TTM Q/Q Growth Statistics
High Average Low
992.56 %
111.69 %
-69.98 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 73
Healthcare Sector # 212
Overall # 1813

Revenue TTM Y/Y Growth Statistics
High Average Low
992.56 %
111.69 %
-69.98 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 73
Sector # 213
S&P 500 # 1823
Cumulative Revenue growth Comment
Although Xencor Inc's Annual Revenue growth year on year were below company's average 111.69% , Revenue announced in the Dec 31 2023 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 2.28% year on year, from -51.09% in Sep 30 2023.

In the Healthcare sector 211 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 233 to 1813.

Revenue TTM Q/Q Growth Statistics
High Average Low
992.56 %
111.69 %
-69.98 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 73
Healthcare Sector # 212
Overall # 1813

Revenue TTM Y/Y Growth Statistics
High Average Low
992.56 %
111.69 %
-69.98 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 73
Sector # 213
S&P 500 # 1823




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
XNCR's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for XNCR's Competitors
Revenue Growth for Xencor Inc's Suppliers
Revenue Growth for XNCR's Customers

You may also want to know
XNCR's Annual Growth Rates XNCR's Profitability Ratios XNCR's Asset Turnover Ratio XNCR's Dividend Growth
XNCR's Roe XNCR's Valuation Ratios XNCR's Financial Strength Ratios XNCR's Dividend Payout Ratio
XNCR's Roa XNCR's Inventory Turnover Ratio XNCR's Growth Rates XNCR's Dividend Comparisons



Companies with similar Revenue fall for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2023
Lipocine Inc 164.58%$ 164.577 millions
Blueprint Medicines Corporation163.28%$ 163.282 millions
Celldex Therapeutics inc 156.11%$ 156.107 millions
Intelgenx Technologies Corp 141.04%$ 141.040 millions
Co diagnostics Inc 140.48%$ 140.476 millions
Aclaris Therapeutics Inc 126.62%$ 126.622 millions
Globus Medical Inc 124.60%$ 124.604 millions
Sanuwave Health Inc 124.26%$ 124.259 millions
Roivant Sciences Ltd 117.80%$ 117.804 millions
Intelligent Bio Solutions Inc 114.22%$ 114.216 millions
Pacific Biosciences Of California Inc 113.62%$ 113.622 millions
Docgo Inc 112.37%$ 112.366 millions
Ionis Pharmaceuticals Inc112.32%$ 112.319 millions
Encompass Health Corporation109.55%$ 109.546 millions
Xencor Inc106.80%$ 106.798 millions
Volitionrx Limited103.79%$ 103.795 millions
Innovative Eyewear Inc 103.16%$ 103.159 millions
Coherus Biosciences inc 101.81%$ 101.808 millions
Palatin Technologies Inc 98.18%$ 98.176 millions
Hutchmed china Limited96.52%$ 96.525 millions
Immunitybio inc 90.41%$ 90.411 millions
Alimera Sciences Inc 89.98%$ 89.978 millions
Procept Biorobotics Corporation83.65%$ 83.652 millions
Ptc Therapeutics inc 83.41%$ 83.412 millions
Catalyst Pharmaceuticals Inc 81.98%$ 81.984 millions
Enovis Corporation79.22%$ 79.224 millions
Esperion Therapeutics inc 71.38%$ 71.378 millions
Electrocore Inc 71.37%$ 71.367 millions
Cvrx inc70.81%$ 70.805 millions
Elite Pharmaceuticals Inc 68.64%$ 68.637 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com